Synapse - Works

Results (13087)

A phase I study of FT819, a first-of-kind, off-the-shelf, iPSC-derived TCR less CD19 CAR T cell therapy for the treatment of relapsed/refractory b-cell malignancies

Meeting Abstract

Park, J. H.; Jain, N.; Chen, A.; McGuirk, J. P.; Diaz, M.; Valamehr, B.; Chu, Y. W.; Castro, J. E.
Blood (2020)

Fulltext@MSK | Save

Costs of postinfusion monitoring by site of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who received third-line or later treatment with lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH trials

Meeting Abstract

Palomba, M. L.; Jun, M. P.; Garcia, J.; Lymp, J.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Nguyen, A.
Blood (2020)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
Blood (2020)

Fulltext@MSK | Save

Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study

Meeting Abstract

Patel, K.; Ramchandren, R.; Maris, M.; Lesokhin, A. M.; von Keudell, G. R.; Cheson, B. D.; Zonder, J.; Seymour, E. K.; Catalano, T.; Lin, G. H. Y.; more...
Blood (2020)

Fulltext@MSK | Save

Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 mutant and wildtype lymphoma

Meeting Abstract

Owusu-Ansah, F.; Afaghani, J.; Lee, S.; Taylor, J.
Blood (2020)

Fulltext@MSK | Save

Impact of COVID19 pandemic on an international MPN patient population: Survey results from 1560 MPN patients

Meeting Abstract

Palmer, J. M.; Mead-Harvey, C.; Harrison, C.; Dueck, A. C.; Eckert, R.; Kosiorek, H. E.; Muxi, P.; Pemmaraju, N.; Arguelles, G. R.; Vannucchi, A. M.; more...
Blood (2020)

Fulltext@MSK | Save

Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in TRANSCEND NHL 001

Meeting Abstract

Palomba, M. L.; Gordon, L. I.; Siddiqi, T.; Abramson, J. S.; Kamdar, M.; Lunning, M. A.; Maloney, D. G.; Andreadis, C.; Arnason, J. E.; Ghosh, N.; more...
Blood (2020)

Fulltext@MSK | Save

HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) - health-related quality of life (HRQoL) analysis

Meeting Abstract

Oriol, A.; Richardson, P. G.; Mateos, M. V.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
Blood (2020)

Fulltext@MSK | Save

A phase 1 single dose escalation study of palifermin administered pre-transplant conditioning in subjects undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation

Meeting Abstract

Ostojic, A.; Holtzman, N. G.; Curtis, L. M.; Shaffer, B. C.; Rubin, J. S.; Hakim, F. T.; Mays, J. W.; Heller, T.; Cowen, E. W.; Werner, S.; more...
Blood (2020)

Fulltext@MSK | Save

Targeted integration of a CAR at a novel genomic safe harbor directs potent therapeutic outcomes

Meeting Abstract

Odak, A.; Yuan, H.; Feucht, J.; Mansilla-Soto, J.; Eyquem, J.; Leslie, C.; Sadelain, M.
Blood (2020)

Fulltext@MSK | Save